Generate Biomedicines
PublicGenerate Biomedicines is now publicly traded
The data on this page reflects Generate Biomedicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 27, 2026
Last Round
Corporate Funding
Dec 18, 2024
Total Funding Raised
$1.11B
Company Overview
Generate Biomedicines is a biotechnology company that utilizes a generative biology platform to create innovative drugs across various protein modalities and therapeutics.
Sector
Biotech
Verticals
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
AI Layer
Application
Keywords
Generate Biomedicines Comparables
Compare Generate Biomedicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbSci | 87% | |
| Chai Discovery | 84% | |
| Insilico Medicine | 83% |
Generate Biomedicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 27, 2026 | ||||
| Corporate Funding | Dec 18, 2024 | ||||
| Corporate Funding | Sep 24, 2024 | ||||
| Series C | Sep 14, 2023 | ||||
| Series B | Nov 18, 2021 | ||||
Series A | Sep 10, 2020 |
Key People
Founding team and executive leadership
Generate Biomedicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series B |
| Pictet Group | Series C |
| Mirae Asset | Series C |
| Guggenheim Securities | IPO |
| Altitude Life Science Ventures | Series B, Series C |
| MAPS Capital Management | Series C |
| ARCH Venture Partners | Series B, Series C |
Recent news
Latest coverage and updates
- is_developingOct 14, 2026
On Oct 14th '26, Generate Biomedicines enters a strategic collaboration and licensing agreement with Zealand Pharma to develop AI-designed protein drugs for obesity and other metabolic diseases in the United States and Denmark; Generate Biomedicines handles research through drug-candidate selection, while Zealand Pharma takes over clinical development, regulatory processes, and global commercialization.
- is_developingOct 14, 2026
In 2026, Generate Biomedicines allocates around $300 million from its IPO proceeds to develop lead candidate GB-0895, a long-acting anti-TSLP antibody, for patients with severe asthma whose symptoms are inadequately controlled by current therapies.
- is_developingOct 13, 2026
On Oct 13th '26, Generate Biomedicines partners with Zealand Pharma to develop protein-based treatments for obesity and other metabolic diseases using AI, with Generate leading research through lead-candidate selection and Zealand overseeing clinical development, regulatory submissions, and commercialization.
- attends_eventAug 27, 2026
Generate Biomedicines attended event ERS Congress 2026 on Jul 1st '26.
- has_revenueAug 27, 2026
Generate Biomedicines had revenue of $6.31M on Aug 27th '26.
Generate Biomedicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access